All News
Pfizer has filed a lawsuit against execs at Regor Therapeutics after an investigation pointing company trade secrets were used to develop therapeutics at the center of Regor’s partnership with Eli Lilly.
J&J said it was terminating development of bermekimab for atopic dermatitis after looking at additional efficacy data.
The Omicron surge appears to be waning in the U.S., but a subvariant of Omicron seems to be surging in other countries where the Omicron surge faded.
Gilead Sciences revealed in a call with analysts that the hold has now been expanded to additional magrolimab studies.
The funds raised will advance several of Dewpoint’s programs to IND status with the FDA and enhance its multi-component biology platform and AI-driven data science platform.
A new study published in the journal Nature found that two patients with leukemia who were treated with CAR T-cell therapy are still in remission 10 years later.
Janssen will provide its proprietary antibodies for research, while Mersana will contribute its proprietary Dolasynthem platform to target cancers with large unmet medical needs.
Up to 40% of AD patients were found to have Lewy Bodies in their brain after succumbing to the disease.
Humira will begin to lose exclusivity in 2023, and numerous biosimilar competitors are waiting to break in on the drug’s lucrative market.
The global women’s health company took another step in its initiative to encourage healthcare equality for women by declaring March 8, International Women’s Day, an annual holiday.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Shares of LogicBio Therapeutics have fallen more than 57% this morning after the company announced that its gene therapy for pediatric patients with methylmalonic acidemia has been placed on clinical hold by the U.S. Food and Drug Administration.
The press release has been shrouded with controversy, and the company’s stock fell 16% despite the seemingly optimistic results.
Finally, Pfizer has submitted the request to FDA to grant emergency use status to their vaccine for children. Here’s everything you should know about the vaccine.
Even as Novartis entertains the potential sale of Sandoz, the company is lauding growth in its biosimilars business that is expected to stabilize its future development.
The portfolio of STING inhibitors is designed to treat autoimmune and inflammatory diseases.
Details about the U.S. government’s contract with Pfizer for 10 million doses of Paxlovid are emerging, with some unusual elements.
In a new “Measuring the Return from Pharmaceutical Innovation” report by Deloitte’s Center for Health Solutions, returns from R&D innovation are up by 7% across the industry.
Regeneron and Sanofi’s anti-inflammatory drug Dupixent has shown to be effective against five types of type 2 inflammations, with more indications expected to surface soon.
Second guessing yourself at each stage of decision-making is a bad practice. Therefore, learning how to avoid it becomes crucial and this article will help you with that.